Estimation of Cardiovascular Risk in Patients With Crohn's Disease and Ulcerative Colitis (PROVACI)
Launched by IRCCS POLICLINICO S. DONATO · Jul 23, 2025
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with confrimed diagnosis of Crohn's disease and Ulcerative colitis-
- Exclusion Criteria:
- • No willing to sign the informe content and have 2 years of follow-up
About Irccs Policlinico S. Donato
IRCCS Policlinico S. Donato is a leading Italian research hospital and clinical trial sponsor dedicated to advancing medical science through innovative research and patient care. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it is recognized for its commitment to high-quality clinical research and the integration of scientific investigation with clinical practice. The institution specializes in various medical fields, including cardiology, oncology, and neurology, and collaborates with universities and research organizations to facilitate cutting-edge studies. With a focus on improving patient outcomes and contributing to public health, IRCCS Policlinico S. Donato plays a pivotal role in the development of new therapies and treatment protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Donato Milanese, Milan, Italy
Patients applied
Trial Officials
Vito Annese, Prof
Principal Investigator
IRCCS Policlinico San Donato, Universita' Vita-Salute San Raffeele, Milano, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported